Escitalopram
- Generic Name
- Escitalopram
- Brand Names
- Cipralex, Lexapro
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 128196-01-0
- Unique Ingredient Identifier
- 4O4S742ANY
- Background
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...
- Indication
Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...
- Associated Conditions
- Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
- Associated Therapies
- -
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 370212
- Registration Number
- NCT04446039
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Alto Neuroscience
- Registration Number
- NCT04388202
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Emory University
- Target Recruit Count
- 18
- Registration Number
- NCT04352101
- Locations
- 🇺🇸
Emory Clinic, Atlanta, Georgia, United States
The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms
- Conditions
- Interventions
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 46
- Registration Number
- NCT04336228
- Locations
- 🇩🇰
Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 84
- Registration Number
- NCT04245748
- Locations
- 🇺🇸
University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 60
- Registration Number
- NCT04245436
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study
- Conditions
- Interventions
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 1
- Registration Number
- NCT04162522
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦Queen's University, Kingston, Ontario, Canada
The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 180
- Registration Number
- NCT04156425
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Sadat City University
- Target Recruit Count
- 80
- Registration Number
- NCT04069819
- Locations
- 🇪🇬
Faculty of Medicine, Shibīn Al Kawm, Egypt
Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Peking University Sixth Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT04013464
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.